Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Colorcon
Harvard Business School
Chinese Patent Office
Cantor Fitzgerald
Moodys
Farmers Insurance
Boehringer Ingelheim
Baxter

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090130

« Back to Dashboard

NDA 090130 describes PACLITAXEL, which is a drug marketed by Accord Hlthcare, Actavis Totowa, Fresenius Kabi Oncol, Hospira, Mylan, Mylan Labs Ltd, Pliva Lachema, Sandoz Inc, Teva Pharms, Teva Pharms Usa, and West-ward Pharms Int, and is included in twelve NDAs. It is available from seven suppliers. Additional details are available on the PACLITAXEL profile page.

The generic ingredient in PACLITAXEL is paclitaxel. There are sixty-nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the paclitaxel profile page.
Summary for 090130
Tradename:PACLITAXEL
Applicant:Actavis Totowa
Ingredient:paclitaxel
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 090130
Physiological EffectMicrotubule Inhibition
Medical Subject Heading (MeSH) Categories for 090130
Suppliers and Packaging for NDA: 090130
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PACLITAXEL paclitaxel INJECTABLE;INJECTION 090130 ANDA Sagent Pharmaceuticals 25021-213 N 25021-213-05
PACLITAXEL paclitaxel INJECTABLE;INJECTION 090130 ANDA Sagent Pharmaceuticals 25021-213 N 25021-213-50

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength6MG/ML
Approval Date:Dec 9, 2009TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Department of Justice
Dow
Cerilliant
Harvard Business School
Colorcon
Moodys
Accenture
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.